FIGHT-302: A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Sponsor

Incyte Corporation (Industry)

Overall Status

Recruiting

CT.gov ID

NCT03656536

Collaborator

(none)

434

Enrollment

210

Locations

Arms

104.5

Anticipated Duration (Months)

2.1

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Condition or Disease	Intervention/Treatment	Phase
Unresectable Cholangiocarcinoma Metastatic Cholangiocarcinoma	Drug: Pemigatinib Drug: Gemcitabine Drug: Cisplatin	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

434 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Actual Study Start Date :

Jun 3, 2019

Anticipated Primary Completion Date :

Mar 20, 2027

Anticipated Study Completion Date :

Feb 18, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pemigatinib	Drug: Pemigatinib Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks). Other Names: INCB054828
Active Comparator: Gemcitabine + Cisplatin Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.	Drug: Gemcitabine Gemcitabine 1000 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles. Drug: Cisplatin Cisplatin 25 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Arm

Intervention/Treatment

Experimental: Pemigatinib

Drug: Pemigatinib

Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).

Other Names:

INCB054828

Active Comparator: Gemcitabine + Cisplatin

Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.

Drug: Gemcitabine

Gemcitabine 1000 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Drug: Cisplatin

Cisplatin 25 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Outcome Measures

Primary Outcome Measures

Progression-free survival [Up to approximately 12 months]
Defined as the time from date of randomization until date of disease progression (according to Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 and assessed by an independent central reviewer (ICR)) or death, whichever occurs first.

Secondary Outcome Measures

Overall response rate [Up to approximately 12 months]
Defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR.
Overall survival [Up to approximately 12 months]
Defined as the time from date of randomization until death due to any cause.
Duration of response [Up to approximately 12 months]
Defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurs first.
Disease control rate [Up to approximately 12 months]
Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease (SD) per RECIST v1.1 as assessed by an ICR.
Number of treatment-emergent adverse events [Up to approximately 12 months]
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
Quality of Life impact as assessed by the EQ-5D-3L questionnaire [Up to 12 months]
Quality of Life impact as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire [Up to 12 months]
Quality of Life impact as assessed by the EORTC QLQ-BIL21 questionnaire [Up to 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male and female participants at least 18 years of age at the time of signing the informed consent form (ICF).
Histologically or cytologically confirmed cholangiocarcinoma that is previously untreated and considered unresectable and/or metastatic (Stage IV per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual).
Radiographically measurable or evaluable disease by CT or MRI per RECIST v1.1 criteria.
Eastern Cooperative Oncology Group performance status 0 to 1.
Documented FGFR2 rearrangement.
Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

Received prior anticancer systemic therapy for unresectable and/or metastatic disease (not including adjuvant/neo-adjuvant treatment completed at least 6 months prior to enrollment, and participants that have received treatment for locally advanced disease with trans-arterial chemoembolization or selective internal radiation therapy, if clear evidence of radiological progression is observed before enrollment, or enrolled as of Amendment 6 (or Amendment 5-JP2) and the participant received 1 cycle of gemcitabine plus cisplatin [the start of study drug {Cycle 1 Day 1} must be at least 14 days and ≤ 4 weeks {28 days} from the last dose of gemcitabine plus cisplatin]).
Child-Pugh B and C.
Toxicities related to prior therapy(ies) must be Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ Grade 1 at the time of screening.
Concurrent anticancer therapy, other than the therapies being tested in this study.
Participant is a candidate for potentially curative surgery.
Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination.
Radiation therapy administered within 4 weeks of enrollment/randomization/first dose of study treatment.
Known central nervous system (CNS) metastases or history of uncontrolled seizures.
Known additional malignancy that is progressing or requires active treatment (exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
Laboratory values at screening outside the protocol-defined range.
History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues, such as the skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
Significant gastrointestinal disorders that could interfere with absorption, metabolism, or excretion of pemigatinib.
Clinically significant or uncontrolled cardiac disease.
History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically meaningful.
Chronic or current active infectious disease requiring systemic antibiotics or antifungal or antiviral treatment within 2 weeks prior to enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed). Note: HIV-positive participants are allowed if all of the following criteria are met: CD4+ count ≥ 300/µL, undetectable viral load, receiving antiretroviral therapy that does not interact with study drug, and no HIV/AIDS-associated opportunistic infection in the last 12 months.
Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment. Note: Moderate CYP3A4 inhibitors are not prohibited
Known hypersensitivity or severe reaction to pemigatinib, gemcitabine, cisplatin, or their excipients.
Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic Arizona	Phoenix	Arizona	United States	85054
2	Marin Cancer Care	Greenbrae	California	United States	94904
3	Georgetown University - Lombardi Comprehensive Cancer Center	Washington	District of Columbia	United States	20007
4	Mayo Clinic - Florida	Jacksonville	Florida	United States	32224
5	Mount Sinai Medical Center Comprehensive Cancer Center	Miami Beach	Florida	United States	33140
6	Winship Cancer Institute of Emory University	Atlanta	Georgia	United States	30322
7	University of Chicago Medical Center	Chicago	Illinois	United States	60637-1447
8	Parkview Research Center	Fort Wayne	Indiana	United States	46845
9	University of Iowa Hospital and Clinics	Iowa City	Iowa	United States	52242
10	The University of Kansas Cancer Center	Westwood	Kansas	United States	66205
11	Ochsner Clinic Foundation Ocf Ochsner Cancer Institute Oci	New Orleans	Louisiana	United States	70121
12	Johns Hopkins Oncology Center	Baltimore	Maryland	United States	21287
13	Boston Medical Center	Boston	Massachusetts	United States	02118
14	Beth Israel Deaconess Medical Center	Boston	Massachusetts	United States	02215
15	Barbara Ann Karmanos Cancer Hospital	Detroit	Michigan	United States	48201
16	Henry Ford Hospital	Detroit	Michigan	United States	48202
17	Karmanos Cancer Institute	Farmington Hills	Michigan	United States	48334
18	Mayo Clinic	Rochester	Minnesota	United States	55905
19	Comprehensive Cancer Centers of Nevada - Twain	Las Vegas	Nevada	United States	89169
20	Summit Medical Group	Florham Park	New Jersey	United States	07932
21	Icahn School of Medicine At Mount Sinai	New York	New York	United States	10029
22	University of Rochester, James P. Wilmot Cancer Center	Rochester	New York	United States	14642
23	White Plains Hospital	White Plains	New York	United States	10601
24	University Hospitals Cleveland Medical Center	Cleveland	Ohio	United States	44106
25	Cleveland Clinic Foundation	Cleveland	Ohio	United States	44195
26	Providence Portland Med. Ctr	Portland	Oregon	United States	97213
27	Oregon Health & Science University	Portland	Oregon	United States	97239
28	Fox Chase Cancer Center	Philadelphia	Pennsylvania	United States	19111
29	Greenville Hospital System University Medical Center Institute For Translational Oncology Research	Greenville	South Carolina	United States	29605
30	Baylor Scott and White Research Institute	Dallas	Texas	United States	75246
31	Houston Methodist Research Institute	Houston	Texas	United States	77030
32	Riverside Regional Medical Center	Newport News	Virginia	United States	23601
33	Virginia Mason Medical Center	Seattle	Washington	United States	98101
34	West Virginia University Cancer Institute	Morgantown	West Virginia	United States	26506
35	Aurora Research Institute	Wauwatosa	Wisconsin	United States	53226
36	Landeskrankenhaus Universitatsklinikum Graz	Graz		Austria	08036
37	Innsbruck University Hospital	Innsbruck		Austria	A-6020
38	Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz	Linz		Austria	04010
39	Salzburger Universitatsklinikum	Salzburg		Austria	05020
40	Landeskrankenhaus Steyr	Steyr		Austria	04400
41	Allgemeines Krankenhaus Der Stadt Wien	Vienna		Austria	01090
42	Ulb Hospital Erasme	Bruxelles		Belgium	01070
43	Universitair Ziekenhuis Brussel	Bruxelles		Belgium	01090
44	Universitair Ziekenhuis Gent	Gent		Belgium	09000
45	Hospital de Jolimont	Haine-st-paul		Belgium	07100
46	Az Groeninge Campus Kennedylaan	Kortrijk		Belgium	08500
47	Universitaire Ziekenhuis Leuven - Gasthuisberg	Leuven		Belgium	03000
48	Chu Ucl Namur University Hospital Mont-Godinne	Yvoir		Belgium	05530
49	Princess Margaret Cancer Center	Toronto	Ontario	Canada	MG5 2M9
50	Peking Union Medical College Hospital	Beijing		China	100032
51	West China Hospital Sichuan University	Chengdu		China	610041
52	Fujian Cancer Hospital	Fuzhou		China	350005
53	Sun Yat-Sen Memorial Hospital Sun Yat-Sen University	Guangdong		China	510000
54	Sun Yat-Sen Memorial Hospital Sun Yat-Sen University	Guangzhou		China	510000
55	The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou		China	310009
56	Heilongjiang Province Cancer Hospital	Harbin		China	150081
57	University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)	Hefei		China	230001
58	Kunming 1St People'S Hospital	Kunming		China	650032
59	Jiangsu Province Hospital	Nanjing		China	210029
60	The Affiliated Hospital of Qingdao University	Shandong		China	266071
61	Zhongshan Hospital Fudan University	Shanghai		China	200032
62	Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai		China	200092
63	Xinhua Hospital	SHanghai		China	200092
64	Sichuan Cancer Hospital	Sichuan		China	610041
65	Tianjin Medical University Cancer Institute Hospital	Tianjin		China	300060
66	Tongji Hospital Huazhong University of Science and Technology	Wuhan		China	430030
67	Hubei Cancer Hospital	Wuhan		China	430079
68	Northern Jiangsu Peoples Hospital	Yangzhou		China	225001
69	Herlev Og Gentofte Hospital	Herlev		Denmark	02730
70	Docrates Cancer Center	Helsinki		Finland	00180
71	Helsinki University Central Hospital	Helsinki		Finland	00290
72	Tampere University Hospital	Tampere		Finland	33521
73	Institut Sainte Catherine	Avignon Cedex 9		France	84918
74	Chu Besancon Hospital Jean Minjoz	Besancon		France	25030
75	Institut Bergonie	Bordeaux Cedex		France	33076
76	Hopital Beaujon	Clichy		France	92110
77	Hopital Prive Jean Mermoz	Lyon Cedex 08		France	69373
78	Chu Hopital de La Timone	Marseille Cedex 5		France	13385
79	Centre Hospitalier Universitaire de Nantes	Nantes		France	44000
80	Centre Antoine Lacassagne	Nice Cedex 02		France	06189
81	Hospital Universitaire Pitie-Salpetriere	Paris Cedex 13		France	75013
82	Hopital Europeen Georges Pompidou (Hegp)	Paris Cedex 15		France	75015
83	Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque	Pessac Cedex		France	336600
84	Hospital de La Miletrie	Poitiers Cedex		France	86021
85	Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume	Rouen Cedex		France	76031
86	Chu de Saint-Etienne	Saint Etienne		France	42055
87	Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau	Saint Herblain		France	44800
88	Chu Toulouse Hopital Rangueil	Toulouse Cedex 9		France	31059
89	Chu Vandoeuvre-Les-Nancy Hopital Brabois	Vandoeuvre Les Nancy		France	54511
90	Institut Gustave Roussy	Villejuif Cedex		France	94805
91	University Medical Center Rwth Aachen	Aachen		Germany	52074
92	Charite - Campus Virchow-Klinikum	Berlin		Germany	13353
93	Charite Universitaetsmedizin Berlin - Campus Charite Mitte	Berlin		Germany	13353
94	Universitatsklinikum Bonn Aoer	Bonn		Germany	53127
95	Klinikum Bremen-Nord	Bremen		Germany	28755
96	University Clinic Carl Gustav Carus Technical University Dresden	Dresden		Germany	01307
97	Klinikum Der Johann Wolfgang Goethe University	Frankfurt		Germany	60590
98	University Medical Center Freiburg	Freiburg		Germany	79106
99	Universitatsklinikum Hamburg Eppendorf	Hamburg		Germany	20246
100	Asklepios Klinik Altona	Hamburg		Germany	22763
101	Hannover Medical School	Hannover		Germany	30625
102	Universitaetsklinikum Des Saarlandes	Homburg / Saar		Germany	66421
103	Universitatsklinikum Koln	Koln		Germany	50937
104	Universitatsklinikum Leipzig Aor	Leipzig		Germany	04103
105	Klinikum Ludwigsburg	Ludwigsburg		Germany	71640
106	OTTO-VON-GUERICKE-UNIVERSITï¿½T MAGDEBURG	Magdeburg		Germany	39120
107	Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii	Mainz		Germany	55131
108	University Hospital Grosshadern Munich	Munich		Germany	81377
109	Klinikum Nuernberg	Nuernberg		Germany	90419
110	Universitaetsklinikum in Tubingen	Tubingen		Germany	72076
111	University Hospital Tuebingen	Tubingen		Germany	72076
112	UNIVERSITï¿½TSKLINIKUM ULM	ULM		Germany	89081
113	St. Vincent'S University Hospital	Dublin 4		Ireland	D04 Y8V0
114	Soroka University Medical Center	Beer-sheva		Israel	84001
115	Rambam Health Care Campus	Haifa		Israel	3109601
116	Hadassah University Hospital	Jerusalem		Israel	9112001
117	Rabin Medical Center - Beilinson Hospital	Petach Tikva		Israel	4941492
118	Tel Aviv Sourasky Medical Center	Tel Aviv		Israel	64239
119	Azienda Ospedaliero Universitaria Ospedali Riuniti	Ancona		Italy	60126
120	Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari	Bari		Italy	70124
121	Ospedale Papa Giovanni Xxiii	Bergamo		Italy	24127
122	L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA ï¿½ MALPIGHI	Bologna		Italy	40138
123	Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo	Candiolo		Italy	10060
124	Presidio Ospedaliero Garibaldi Nesima	Catania		Italy	95100
125	Ospedale Degli Infermi - Faenza	Faenza		Italy	48018
126	Irccs Azienda Ospedaliera Universitaria San Martino	Genova		Italy	16132
127	Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele	Milan		Italy	20132
128	Fondazione Irccs Istituto Nazionale Dei Tumori	Milan		Italy	20133
129	European Institute of Oncology	Milan		Italy	20141
130	Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda	Milan		Italy	20162
131	A.O.U. Di Modena - Policlinico	Modena		Italy	41124
132	Istituto Nazionale Tumori Irccs Fondazione Pascale	Napoli		Italy	80131
133	Universita Degli Studi Della Campania Luigi Vanvitelli U.O.C. Oncologia Medica	Napoli		Italy	80138
134	Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano	Orbassano		Italy	10043
135	Iov - Istituto Oncologico Veneto Irccs	Padova		Italy	35128
136	Presidio Ospedaliero Pescara	Pescara		Italy	65124
137	Azienda Ospedaliera Universitaria Pisana	Pisa		Italy	56126
138	Istituto Nazionale Tumori Regina Elena Irccs	Roma		Italy	00144
139	Fondazione Policlinico Universitario Agostino Gemelli Irccs	Roma		Italy	00168
140	Universita Campus Bio Medico Di Roma	Rome		Italy	00128
141	Azienda Ospedaliera San Camillo Forlanini	Rome		Italy	00152
142	Irccs Istituto Clinico Humanitas	Rozzano		Italy	20089
143	Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte	Siena		Italy	53100
144	Centro Ricerche Cliniche Di Verona (Crc)	Verona		Italy	37134
145	San Bartolo Hospital	Vicenza		Italy	36100
146	Aichi Cancer Center Hospital	Aichi		Japan	464 8681
147	University of Tokyo Hospital	Bunkyo		Japan	113-8655
148	Chiba University Hospital	Chiba		Japan	260-8677
149	Chiba Cancer Center	Chiba		Japan	260-8717
150	National Hospital Organization Kyushu Cancer Center	Fukuoka-shi		Japan	812-8582
151	National Hospital Organization Kyushu Cancer Center	Fukuoka		Japan	811-1395
152	Hiroshima University Hospital	Hiroshima-shi		Japan	734-8551
153	Hokkaido University Hospital	Hokkaido		Japan	060-8648
154	Hyogo College of Medicine Hospital	Hyogo		Japan	663-8501
155	Kanazawa University Hospital	Ishikawa		Japan	920-8641
156	Teikyo University Hospital	Itabashi-ku		Japan	173-8606
157	Kobe University Hospital	Kobe		Japan	650-0017
158	Cancer Institute Hospital of Jfcr	Koto-ku		Japan	135-8550
159	Kyoto University Hospital	Kyoto-shi		Japan	606-8507
160	Nho Shikoku Cancer Center	Matsuyama		Japan	791-0280
161	Kyorin University Hospital	Mitaka		Japan	181-8611
162	Niigata Cancer Center Hospital	Niigata		Japan	951-8566
163	Osaka International Cancer Institute	Osaka-shi		Japan	541-8567
164	Kindai University Hospital	Osakasayama City		Japan	589-8511
165	Saitama Cancer Center	Saitama		Japan	362-0806
166	Tohoku University Hospital	Sendai-shi		Japan	980-8574
167	Keio University Hospital	Shinjuku-ku		Japan	160-8582
168	Shizuoka Cancer Center	Shizuoka		Japan	411-8777
169	Osaka University Hospital	Suita-shi		Japan	565-0871
170	Jichi Medical University Hospital	Tochigi		Japan	329-0498
171	Toyama University Hospital	Toyama		Japan	930-0194
172	Yamaguchi University Hospital	UBE		Japan	755-8505
173	Wakayama Medical University Hospital	Wakayama		Japan	641-8509
174	Kanagawa Cancer Center	Yokohama-shi		Japan	241-8515
175	Yokohama City University Medical Center	Yokohama		Japan	232-0024
176	Oita University Hospital	Yufu-shi		Japan	879-5593
177	Amsterdam University Medical Centre	Amsterdam		Netherlands	1100 DD
178	Maastricht Umc+	Maastricht		Netherlands	6202 AZ
179	Erasmus Medical Center	Rotterdam		Netherlands	3015 CE
180	Umc Utrecht	Utrecht		Netherlands	3584 CX
181	Oslo University Hospital	Oslo		Norway	00450
182	Hospital de La Santa Creu I Sant Pau	Barcelona		Spain	08026
183	Hospital General Universitario Vall D Hebron	Barcelona		Spain	08035
184	Hospital Clinic I Provincial	Barcelona		Spain	08036
185	Hospital Clinic de Barcelona	Barcelona		Spain	8036
186	Hospital Universitario Reina Sofia	Cordoba		Spain	14004
187	Hospital Universitario Reina Sofia	Córdoba		Spain	14004
188	Hospital Materno Teresa Herrera	La Coruna		Spain	15006
189	Hospital General Universitario Gregorio Maranon	Madrid		Spain	28007
190	Hospital Universitario Ramon Y Cajal	Madrid		Spain	28034
191	Hospital Universitario Hm Sanchinarro	Madrid		Spain	28050
192	Hospital Regional Universitario de Malaga	Malaga		Spain	29010
193	Clinica Universidad de Navarra (Cun)	Pamplona		Spain	31008
194	Hospital Universitari Parc Tauli	Sabadell		Spain	08208
195	HOSPITAL UNiVERSITARIO DONOSTIA	San Sebastian		Spain	20014
196	Hospital Universitario Marques de Valdecilla	Santander		Spain	39008
197	Hospital General Universitario de Valencia	Valencia		Spain	46014
198	Karolinska Institute Universitetssjukhuset Solna	Solna		Sweden	171 64
199	Inselspital - Universitaetsspital Bern	Bern		Switzerland	03010
200	Universitatsspital Zurich	Zuerich		Switzerland	08091
201	Aberdeen Royal Infirmary	Aberdeen		United Kingdom	AB25 2ZN
202	Addenbrooke'S Hospital	Cambridge		United Kingdom	CB2 0QQ
203	Velindre Cancer Centre	Cardiff		United Kingdom	CF14 2TL
204	University Hospital Coventry and Warwickshire	Coventry		United Kingdom	CV2 2DX
205	The Royal Marsden Nhs Foundation Trust - Chelsea	London		United Kingdom	SW3 6JJ
206	Imperial College Healthcare Nhs Trust - Hammersmith Hospital	London		United Kingdom	W12 0HS
207	University College London Hospitals (Uclh)	London		United Kingdom	WC1E 6BT
208	Kent Oncology Centre - Maidstone Hospital	Maidstone		United Kingdom	ME16 9QQ
209	The Christie Nhs Foundation Trust	Manchester		United Kingdom	M20 4BV
210	The Royal Marsden Nhs Foundation Trust - Sutton	Sutton		United Kingdom	SM2 5PT